Curated, research-grade updates on GLP-1, GLP-3, and peptide-therapy developments from PubMed, the FDA, and ClinicalTrials.gov. No commentary. Just signal.
Annemans L, Johansson E, Spaepen E, et al. — Journal of medical economics
Alhalabi H, Borschel L, Le Foll C, et al. — Journal of pharmaceutical and biomedical analysis
Lempesis IG, Dalamaga M — Metabolism open
Prasad S, Ahuja A, Katwa LC, et al. — JCEM case reports
Rodriguez ME, Lavell J, Foreman RM — The Nurse practitioner
Patil R, Dunn W, Noureddin M, et al. — Drugs
Hepşen S, Haymana C, Ertepe Küçükgöde G, et al. — Obesity facts
Rangraze IR, El-Tanani M, Janez A, et al. — Diabetes therapy : research, treatment and education of diabetes and related disorders
Anderer S — JAMA
Kapoor N, Shaikh S, Bhattacharya S, et al. — Cardiovascular diabetology. Endocrinology reports
Chen R, Zhang J, Chen J, et al. — Kidney & blood pressure research
Remala S, Liang L, Shah AM, et al. — Circulation. Genomic and precision medicine
Neves JS, Leite AR, Vasques-Nóvoa F, et al. — Diabetes, obesity & metabolism
PHASE2 · Recruiting — This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in…
PHASE1, PHASE2 · Recruiting — This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult…
PHASE3 · Completed — This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated…
Craddock N, Schneider J — Body image
Palmisano T, Verma R, Guarraia D, et al. — Heart rhythm
Overgaard RV, Birkhan O, Rathor N, et al. — Diabetes, obesity & metabolism
Mao X, Fan H, Yuen MF, et al. — Hepatology (Baltimore, Md.)
Teke E, Öztürk S, Ulutaş ME, et al. — Obesity surgery
NA · Recruiting — This study will look at how eating peanuts every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding peanuts to meals…
Alawadhi AA, Alroudhan D, Alsaeed DJ, et al. — BMJ open
PHASE3 · Completed — This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe…
Shah J, Makwana B, Panchal K, et al. — American journal of ophthalmology
Ha J, Lester E, De May H, et al. — Journal of reconstructive microsurgery
Awadalla L, Iskander S, Chu C, et al. — Canadian journal of physiology and pharmacology
Hajibandeh S, Tao YA, Hsieh MH, et al. — Journal of the American Pharmacists Association : JAPhA
Fioretti F, Petrie MC, Dickert NW, et al. — Journal of the American College of Cardiology
de Lartigue G, Brierley DI, Choi HJ — Nature reviews. Gastroenterology & hepatology
Liu H, Zhang Y, Feng L, et al. — Nature communications
NA · Recruiting — The aim of the current study is to determine whether resistance exercise and/or protein intake can preserve lean mass and improve physical function in patients with obesity initiating…
PHASE4 · Recruiting — The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes.…
PHASE3 · Active Not Recruiting — This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet…
PHASE3 · Recruiting — The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight.…
PHASE3 · Active Not Recruiting — The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will…
PHASE2 · Recruiting — The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight…
PHASE4 · Recruiting — Tirzepatide, a gut hormone-based medication, has shown promising results in treating obesity, with \~22% weight loss and mild side effects. However, patients with type 2 diabetes typically experience…
PHASE3 · Recruiting — The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity…
Yamauchi T, Becker NP, Hagemann CA, et al. — The lancet. Diabetes & endocrinology
PHASE3 · Recruiting — The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will…
PHASE3 · Recruiting — The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic…
PHASE3 · Active Not Recruiting — The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include…
PHASE1 · Active Not Recruiting — The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site…
PHASE3 · Recruiting — This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated…
PHASE3 · Recruiting — This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis…
Perez-Tilve D, Zhang F, Zhang Y, et al. — Molecular metabolism
Mwala NN, de van der Schueren MAE — Current opinion in clinical nutrition and metabolic care
PHASE1 · Active Not Recruiting — This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to…
PHASE1 · Recruiting — This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study. The purpose of this…
PHASE3 · Active Not Recruiting — The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
PHASE3 · Active Not Recruiting — The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with…
PHASE3 · Active Not Recruiting — The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol)…
PHASE1 · Recruiting — This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period…
Li Q, Cheng W, Zhang J, et al. — Diabetology & metabolic syndrome
PHASE3 · Active Not Recruiting — This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe…
PHASE3 · Active Not Recruiting — This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.…
PHASE3 · Completed — This study is open to adults who are at least 18 years old and have * presumed or confirmed NASH together with overweight or obesity and * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of…
PHASE3 · Active Not Recruiting — This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who…
PHASE3 · Completed — This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe…